Primary Immunodeficiency Disorders Market Report 2026

Primary Immunodeficiency Disorders Market Overview

• Primary Immunodeficiency Disorders market size has reached to $7.3 billion in 2025 • Expected to grow to $10.01 billion in 2030 at a compound annual growth rate (CAGR) of 6.5% • Growth Driver: Increasing Prevalence Of Autoimmune Diseases Driving Growth Of The Market Due To Rising Cases Of Immune System Dysfunction • Market Trend: Innovative Developments In Intravenous Immunoglobulin (IVIG) Therapy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Primary Immunodeficiency Disorders Market?

Primary immunodeficiency disorders (PIDs) are inherited conditions that weaken or impair the immune system, increasing vulnerability to infections, autoimmune diseases, and certain cancers. Identifying and diagnosing primary immunodeficiency disorders early is crucial for timely treatment, infection prevention, and enhancing patient well-being through therapies such as immunoglobulin replacement or bone marrow transplants. The main diseases in primary immunodeficiency disorders are antibody deficiency, cellular immunodeficiency, innate immune disorders, and others. Antibody deficiencies arise when the immune system fails to produce adequate antibodies, which are proteins responsible for identifying and neutralizing harmful pathogens. Available treatments include immunoglobulin replacement therapy, antibiotic therapy, stem cell and bone marrow transplantation, gene therapy, and others. Diagnostic methods encompass genetic testing, blood testing, flow cytometry, and others and are utilized in hospitals, specialty clinics, homecare settings, and research institutions.

What Is The Primary Immunodeficiency Disorders Market Growth Forecast?

The primary immunodeficiency disorders market size is expected to see strong growth in the next few years. It will grow to $10.01 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to increasing advancements in gene therapy research, rising demand for early and accurate diagnosis, expansion of precision immunology treatments, growing investment in rare disease research, increasing integration of ai in diagnostic workflows. Major trends in the forecast period include increasing adoption of genetic testing for early diagnosis, growing use of immunoglobulin replacement therapies, rising focus on personalized treatment approaches, expansion of newborn screening programs, enhanced integration of advanced diagnostic platforms.

What Are The Drivers Of The Primary Immunodeficiency Disorders Market?

The growing prevalence of autoimmune diseases is expected to propel the growth of the primary immunodeficiency disorders market going forward. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells and tissues, treating them as foreign threats. This abnormal response leads to inflammation and damage in various organs and systems. The rise in autoimmune diseases is attributed to a complex interplay of environmental triggers, genetic predispositions, and lifestyle changes. Autoimmune diseases can cause primary immunodeficiency disorders by disrupting immune regulation and targeting immune cells, leading to weakened or dysfunctional immune responses. For instance, in February 2024, according to Arthritis Australia, an Australia-based charitable not-for-profit organisation advocating for people with arthritis and musculoskeletal conditions, by 2025, approximately 562,378 Australians are living with rheumatoid arthritis (RA), accounting for 14% of the total arthritis population. Therefore, the growing prevalence of autoimmune diseases is driving the growth of the primary immunodeficiency disorders industry. The rising emphasis on preventive care is expected to propel the growth of the primary immunodeficiency disorders market going forward. Preventive care encompasses healthcare services and interventions aimed at preventing disease, detecting health conditions early, and promoting overall health and well-being. Preventive care is rising due to increasing awareness of early disease detection, which helps reduce severe health complications and lowers long-term healthcare costs. Primary immunodeficiency disorders highlight the importance of preventive care by demonstrating that early diagnosis and proactive management can prevent severe infections and complications, reinforcing the need for routine screenings and immunological monitoring. For instance, in March 2024, according to a report by the Government of the United Kingdom, a UK-based information website, in March 2023, the percentage of people with type 1 diabetes in England receiving 8 care processes at GP practices participating in the NDA rose to 43.8%, up from 35.2% the previous year. Therefore, the rising emphasis on preventive care is driving the growth of the primary immunodeficiency disorders industry.

Key Players In The Global Primary Immunodeficiency Disorders Market

Major companies operating in the primary immunodeficiency disorders market are Pfizer Inc, Takeda Pharmaceuticals, CSL Behring, Baxter International Inc, Grifols SA, Octapharma, Kedrion Biopharma, LFB Group, ADMA Biologics Inc, Bio Products Laboratory Ltd, Miltenyi Biotec, BD Biosciences, Cellectis SA, X4 Pharmaceuticals Inc, bluebird bio Inc, Chengdu Rongsheng Pharmaceutical Co Ltd, Sanofi SA, Roche Holding AG, Novartis AG, AbbVie Inc, AstraZeneca plc, Gilead Sciences Inc

Global Primary Immunodeficiency Disorders Market Trends and Insights

Major companies operating in the primary immunodeficiency disorders market are focusing on developing advanced therapies such as intravenous immunoglobulin therapy to enhance patient outcomes by improving immune function. Intravenous immunoglobulin (IVIG) therapy is a treatment in which immunoglobulin (antibodies) derived from donor plasma is administered directly into a patient's bloodstream via an IV. For instance, in June 2024, Grifols, a Spain-based healthcare company, received FDA approval for Yimmugo, an intravenous immunoglobulin (IVIg) therapy. This newly developed, sugar-free, ready-to-use IgG solution is derived from human blood plasma and is intended for intravenous administration. Approved in the U.S. for substitution therapy in patients with primary antibody deficiency syndromes, Yimmugo provides antibody replacement to support individuals with immune system deficiencies. It enhances Grifols’ portfolio of plasma-based treatments by offering a safer and more effective option to help protect against infections.

What Defines the Primary Immunodeficiency Disorders Market?

The primary immunodeficiency disorders market consists of revenues earned by entities by providing services such as immunoglobulin therapy, rehabilitation and support programs, educational and advocacy services, and personalized treatment plans. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary immunodeficiency disorders market also includes sales of vaccines, antibiotics, antifungals, and small molecule drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Primary Immunodeficiency Disorders Market Report 2026?

The primary immunodeficiency disorders market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the primary immunodeficiency disorders industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.